Skip to main content

Advertisement

Table 2 Clinical responses of patients with locally advanced breast cancer to neoadjuvant chemotherapy (FEC regimen vs. PE regimen) during each assessments

From: Weekly taxane–anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial

Group First assessment [cases (%)] Second assessment [cases (%)] Third assessment [cases (%)]
FEC arm 151 132 68
 cCR 0 (0.00) 1 (0.76) 3 (4.41)
 cPR 70 (46.36) 76 (57.58) 51 (75.00)
 cSD 67(44.37) 45 (34.09) 13 (19.12)
 cPD 6 (3.97) 7 (5.30) 1 (1.47)
 Missing 8 (5.30) 3 (2.27) 0 (1.47)
PE arm 142 121 49
 cCR 1 (0.70) 6 (4.96) 5 (10.20)
 cPR 97 (68.31) 92 (76.03) 41 (83.67)
 cSD 35 (24.65) 20 (16.53) 2 (4.08)
 cPD 3 (2.11) 3 (2.48) 1 (2.04)
 Missing 6 (4.23) 0 (0.00) 0 (0.00)
  1. FEC tri-weekly 5-fluorouracil–epirubicin–cyclophosphamide regimen, PE weekly paclitaxel–epirubicin regimen, cCR clinical complete response, cPR clinical partial response, cSD clinical stable disease, cPD clinical progressive disease